Back-to-back buybacks for CSL

BLOOD products and flu vaccines supplier CSL will buy back up to $1 billion of its shares over the next 12 months.

CSL's $1 billion share buyback is testament to the strength of the company, John Shine (R) says.

BLOOD products and flu vaccines supplier CSL has announced its biggest ever share buyback, just 12 months after the last one.

CSL, whose share price touched $100 earlier this year for the second time in the company's history, will buy back up to $1 billion of its shares over the next year.